Efficacy of interferon therapy for recurrence-free and overall survival after curative radiofrequency ablation for HCV-related hepatocellular carcinoma.

Efficacy of interferon therapy for recurrence-free and overall survival after curative radiofrequency ablation for HCV-related hepatocellular carcinoma. - IFN Therapy after RFA for HCC

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006761

Enrollment

Registered

2011-11-24

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

PEG-IFN alpha 2a and RBV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients without recurrence of HCC at least three months after curative radiofrequency ablation for naive HCC, first recurrence HCC and second recurrence HCC.

Exclusion criteria

Exclusion criteria: 1)uncontrollable heart disease 2)extrahepatic metastasis of hepatocellular carcinoma 3)another active cancer 4)chronic renal failure 5)taking Shosai-Koto(Chinese medicine) 6)autoimmune and other viral hepatitis 7)depression and psychiatric disease 8)pregnancy and during lactation

Design outcomes

Primary

Measure	Time frame
Recurrence rate	—

Secondary

Measure	Time frame
Overall survival Liver Function Virus eradication	—

Countries

Japan

Contacts

Public ContactShinpei Sato

Kyoundo hospital gastroenterology and hepatology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026